Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

LENZ Therapeutics (LENZ) Gains from Sales and Divestitures (2022 - 2023)

LENZ Therapeutics (LENZ) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $703035.0 as the latest value for Q3 2023.

Quarterly Gains from Sales and Divestitures rose 40.0% to $703035.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $703035.0 through Sep 2023, up 40.0% year-over-year, with the annual reading at $553443.0 for FY2022, N/A changed from the prior year.
Gains from Sales and Divestitures for Q3 2023 was $703035.0 at LENZ Therapeutics, up from $653970.0 in the prior quarter.
The five-year high for Gains from Sales and Divestitures was $703035.0 in Q3 2023, with the low at $398028.0 in Q1 2022.